

B1  
"This application is a continuation application claiming priority under 35 U.S.C. § 120 from Application Serial No. 09/328,329 which issued into U. S. Patent No. 6,377,847 on April 23, 2002, that is a continuation-in-part of Application No. 08/533,979 filed September 26, 1995, now abandoned, which is a continuation-in-part of Application No. 08/129,222 filed September 30, 1993, now abandoned."

SB  
C1  
In the Claims:

Claims 22-69 are pending. Please amend the following claims.

B2  
29. (Once Amended) The iontophoretic drug delivery device of claim 28, wherein the concentration of glycerin is up to 10 wt. %, the concentration of sodium metabisulfite is up to 0.05 wt. %, the concentration of EDTA is up to 0.01 wt. %.

B3  
31. (Once Amended) The iontophoretic drug delivery device of claim 24, wherein the concentration of epinephrine, as measured in weight % of the total weight of the reservoir, is about 0.1 wt. % and the concentration of lidocaine is about 10 wt. %.

B4  
34. (Once Amended) The iontophoretic drug delivery device of claim 33, wherein the one to three return electrodes have a total surface area between 1 to 5 cm<sup>2</sup> and wherein the working electrode has a surface area between 2 to 10 cm<sup>2</sup>.

B<sup>5</sup> 57. (Once Amended) The iontophoretic drug delivery device of claim 56, wherein the lidocaine is present up to 10 wt. % based on the total weight of the reservoir.

B<sup>6</sup> 59. (Once Amended) The iontophoretic drug delivery device of claim 58, wherein the concentration of glycerin is up to 10 wt. %, the concentration of sodium metabisulfite is up to 0.05 wt. %, the concentration of EDTA is up to 0.01 wt. %, all based on the total weight of the reservoir.

60. (Once Amended) The iontophoretic drug delivery device of claim 54, wherein the concentration of epinephrine, as measured in weight % of the total weight of the reservoir, is about 0.1 wt. % and the concentration of lidocaine is about 10 wt. %, all based on the total weight of the reservoir.

B<sup>7</sup> 63. (Once Amended) The iontophoretic drug delivery device of claim 62, wherein the return electrodes have a total surface area from 1 to 5 cm<sup>2</sup> and wherein the working electrode has a surface area from 2 to 10 cm<sup>2</sup>.